Translational Lung Cancer Research · 2022 · 22 citations · 11 references
MedicineImmunologyOncologyImmunizationImmunotherapyInflammationAdverse Events Following ImmunizationCancer ImmunotherapyCancer VaccinesTherapeutic VaccinesVaccinationVaccine-based ImmunotherapyAdverse Vaccine ReactionsCytokine Mediator ReleaseImmune Checkpoint Inhibitor TherapyNon-small Cell Lung Cancer ImmunotherapyNon-small Cell Lung Cancer TherapyNon-small Cell Lung Cancer TreatmentVaccination Before ImmunotherapyVaccine-associated Adverse Event
Background: Cytokine release syndrome (CRS) is caused by the release of inflammatory cytokines that appear during or immediately after administration of a therapeutic antibody and can cause a variety of symptoms. COVID-19 vaccination is effective in cancer patients and prevents breakthrough infections. The safety of vaccines during immune checkpoint inhibitor (ICI) therapy has been reported; however, multiple vaccinations have been developed in recent years, and it is unclear whether repeated vaccinations play a role in the development of CRS in patients receiving ICI. Case Description: A 55-year-old man with stage IV non-small cell lung cancer received ipilimumab and nivolumab maintenance therapy; adverse reactions during the first and second COVID-19 vaccinations (BNT162b2) included injection site pain and slight fever; however, the day after the third COVID-19 vaccination (mRNA-1273), he developed a high fever and lost consciousness. Brain MRI showed parietal meningitis. Cytokine levels (IL-6, sIL-2R, IL-10, IFN-γ) were elevated and Grade 2 liver and renal dysfunction were also observed. As various tests ruled out infection and a PCR test for SARS-CoV-2 was negative, a diagnosis of CRS due to COVID-19 vaccination was made. After steroid therapy, his symptoms improved dramatically. Conclusions: In this case, there was a close association between the time course after vaccination and clinical symptoms of high fever and lost consciousness. Clinicians should be aware of the possibility of vaccine-induced adverse effects such as CRS.
11
The Lancet · 2021 · 685 citations · Full text
UCL Discovery (University College London) · 2021 · 445 citations · Full text
Priority COVID-19 Vaccination for Patients with Cancer while Vaccine Supply Is Limited
Antoni Ribas, Rajarshi Sengupta, Trevan Locke et al. · Cancer Discovery · 2020 · 211 citations · Full text
Medicine, Immunology, Oncology +16